Decade of molecular targeted therapy: abdominal manifestations of drug toxicities--what radiologists should know.
OBJECTIVE
Novel drugs targeting molecular pathways involved in tumor development have revolutionized cancer treatment. Radiologists often focus on therapeutic response when evaluating cancer patients and may miss important signs of drug toxicity. This article familiarizes radiologists with the complications of molecular targeted agents in abdominal solid organs, enabling early identification and appropriate intervention and thus reducing patient morbidity and mortality.


CONCLUSIONS
Knowledge of the common abdominal toxicities--including hepatitis, cholecystitis, pancreatitis, fluid retention, and infection--is crucial for early diagnosis, which may spare patients devastating complications or the need for surgery.
Department of Imaging, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02115, USA.
Stephanie Anne Holler
SA
Howard
Katherine M
KM
Krajewski
Eavan
E
Thornton
Jyothi P
JP
Jagannathan
Kevin
K
O'Regan
James
J
Cleary
Nikhil
N
Ramaiya
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D000068258:Bevacizumab; D056486:Chemical and Drug Induced Liver Injury / Q000000981:diagnostic imaging* / Q000209:etiology; D002764:Cholecystitis / Q000139:chemically induced / Q000000981:diagnostic imaging*; D042241:Early Diagnosis; D004487:Edema / Q000139:chemically induced; D005234:Fatty Liver / Q000139:chemically induced / Q000000981:diagnostic imaging; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D007191:Indazoles; D007239:Infections / Q000139:chemically induced / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy / Q000009:adverse effects*; D009369:Neoplasms / Q000188:drug therapy*; D010195:Pancreatitis / Q000139:chemically induced / Q000000981:diagnostic imaging*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000009:adverse effects; D011860:Radiography, Abdominal / Q000379:methods*; D013449:Sulfonamides / Q000009:adverse effects; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D055815:Young Adult
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; C516667:pazopanib; D011505:Protein-Tyrosine Kinases